SCHEMBL370309

SCHEMBL370309

CCOC(=O)c1sc(N)nc1-c1cn(Cc2ccc(OC)cc2)nc1C(O)CC

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.45
HSD17B10 Q99714 3/20 0.45
CDC7 O00311 2/20 0.41
DBF4 Q9UBU7 2/20 0.41
FBP1 P09467 1/20 0.40
HPGD P15428 4/20 0.40
KDM4E B2RXH2 4/20 0.40
GAA P10253 3/20 0.40
GLA P06280 2/20 0.40
MAPK1 P28482 2/20 0.40
NPSR1 Q6W5P4 2/20 0.40
USP2 O75604 1/20 0.40
CASP1 P29466 1/20 0.40
CASP7 P55210 1/20 0.40
CYP1A2 P05177 2/20 0.39
MAPT P10636 4/20 0.38
NPC1 O15118 2/20 0.38
MEN1 O00255 1/20 0.38
TP53 P04637 1/20 0.38
CASP3 P42574 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL370777 0.85 MEN1 (0.36) ALDH1A1FBP1HPGDKDM4EMAPT
SCHEMBL370255 0.82 DHODH (0.44) ALDH1A1CDC7DBF4HPGDKDM4E
SCHEMBL15182514 0.77 CDC7 (0.46) ALDH1A1HSD17B10CDC7DBF4HPGD
SCHEMBL6837459 0.74 RXFP1 (0.42) ALDH1A1CDC7DBF4HPGDKDM4E
SCHEMBL371005 0.74 CDC7 (0.41) ALDH1A1HSD17B10CDC7DBF4HPGD
SCHEMBL28723241 0.73 ALDH1A1 (0.76) ALDH1A1HSD17B10CDC7DBF4FBP1
SCHEMBL369164 0.72 ALDH1A1 (0.48) ALDH1A1HSD17B10HPGDKDM4EGAA
SCHEMBL370870 0.72 CACNA1G (0.40) GLAMAPTNPC1MEN1KMT2A
SCHEMBL369532 0.72 KMT2A (0.37) ALDH1A1HSD17B10HPGDKDM4EGAA
SCHEMBL15182528 0.72 CDC7 (0.40) ALDH1A1HSD17B10CDC7DBF4HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS MERCK SHARP & DOHME CORP. 2013-09-26 US disclosed
EP-2593277-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX Pharma S.A. (CH) 2013-05-22 EP disclosed
WO-2012009000-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA S.A. (CH) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS GRM4, GRM1, GRM3 ALDH1A1 3331/4885HSD17B10 3011/4885CDC7 4513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.